Informatica Has Positive Catalysts Ahead, Seattle Genetics Has Impressive Trial Results

Informatica Corporation (NASDAQ:INFA): After Informatica reported stronger than expected Q4 results, Oppenheimer expects the company to benefit from strong demand for its products. The firm believes that the company’s stocks has several positive upcoming catalysts and it maintains an Outperform rating.

Seattle Genetics Inc. (NASDAQ:SGEN): After Seattle Genetics announced interim Phase I results for its Adcetris treatment for lymphoma, Oppenheimer believes that the early overall response rates in the trial were impressive. The firm thinks that the drug could ultimately be used to treat additional CD30+ hematologic malignancies, and it maintains an Outperform rating on the stock.

InvenSense Inc (NASDAQ:INVN): After InvenSense reported higher than expected EPS for its December quarter, Oppenheimer expects the company to benefit from the launch of Microsoft’s (NASDAQ:MSFT) Windows 8 and smart TVs. The firm maintains an Outperform rating.

Avnet Inc. (NYSE:AVT): Brean Murray raised its price target on Avnet following solid Q2 results. The firm cited opportunity for margin expansion and management guidance. Shares are Buy rated.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at